Merck has invested € 70 million in the expansion of its antibody-drug conjugates (ADC) manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri, USA.

The investment is expected to triple the facilities’ existing capacity and enhance the company’s contract development and manufacturing organization (CDMO) offering. As part of the expansion, the project will upgrade 3200 square metres to benefit the Process and Analytical Development, Quality Control, Research and Development, Manufacturing, and Logistics departments, whilst also adding new labs, a dedicated manufacturing buffer preparation facility, and a cold storage and a GMP-controlled room temperature (CRT) warehouse that will be located close to the existing facility.